title: Prognostic significance of serum c-erbB-2 protein in breast cancer patients.
abstract: The tissue expression of c-erbB-2 protein in breast cancer is a marker of poor prognosis in a number of studies. More recently it has also been suggested that c-erbB-2 expression may predict response to systemic therapy in patients with advanced breast cancer. The measurement of c-erbB-2 protein in the serum of breast cancer patients has now been reported, but the significance of this finding is not clear. In this study an ELISA assay was used to measure c-erbB-2 in the sera of 23 normal controls, 46 benign breast disease patients, and 119 breast cancer patients. Elevated serum c-erbB-2 protein levels were detected in 13% (3/23) of normal controls, 15% (7/46) of benign disease patients, 15% (7/46) of Stage I/II patients, 26% (9/35) of Stage III patients, and 21% (8/38) of Stage IV patients. The tissue expression of the c-erbB-2 protein showed no association with detection of the serum c-erbB-2 protein (p = 0.31). In the 67 Stage III and IV patients who had assessable disease the presence of the c-erbB-2 protein in the serum bore no relationship to response to hormonal therapy (p = 0.71). Serum detection of the c-erbB-2 protein in Stage I/II patients predicted for a worsening of both survival outcome (p = 0.002) and disease free interval (p = 0.002). A worse outcome was also seen for the Stage III patients (p = 0.04) and Stage IV patients, although the latter did not reach statistical significance (p = 0.27). This study found that the presence of c-erbB-2 in the serum of breast cancer patients was of prognostic significance for all stages of disease.
authors.affiliation: Professorial Department of Surgery, City Hospital, Nottingham, UK.
authors.forename: P C
authors.initials: PC
authors.lastname: Willsher
authors.forename: J
authors.initials: J
authors.lastname: Beaver
authors.forename: S
authors.initials: S
authors.lastname: Pinder
authors.forename: J A
authors.initials: JA
authors.lastname: Bell
authors.forename: I O
authors.initials: IO
authors.lastname: Ellis
authors.forename: R W
authors.initials: RW
authors.lastname: Blamey
authors.forename: J F
authors.initials: JF
authors.lastname: Robertson
mesh_terms: D014408:Biomarkers, Tumor / Q000097:blood*; D001941:Breast Diseases / Q000097:blood; D001943:Breast Neoplasms / Q000097:blood*; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D006801:Humans; D009363:Neoplasm Proteins / Q000097:blood*; D009367:Neoplasm Staging; D011379:Prognosis; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000097:blood*; D012016:Reference Values
chemical_list: D014408:Biomarkers, Tumor; D009363:Neoplasm Proteins; D018719:Erb-b2 Receptor Tyrosine Kinases